A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract

Trial Profile

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Renal cancer; Squamous cell cancer; Ureteral-neoplasms; Urethral cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top